Referências
Artigos de referência
1. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019 Sep;71(9):1400-12.Texto completo Resumo
2. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 Sep;40(9):1725. Resumo
3. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271-7.Texto completo Resumo
4. Systemic Lupus International Collaborating Clinics. SLICC classification criteria for systemic lupus erythematosus. 2012 [internet publication].Texto completo
5. Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018 Apr;93(4):789-96.Texto completo Resumo
6. Rees F, Doherty M, Grainge MJ, et al. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford). 2017 Nov 1;56(11):1945-61.Texto completo Resumo
7. Stojan G, Petri M. Epidemiology of systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2018 Mar;30(2):144-50.Texto completo Resumo
8. Rees F, Doherty M, Grainge M, et al. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. Ann Rheum Dis. 2016 Jan;75(1):136-41.Texto completo Resumo
9. Mitchet CJ Jr, McKenna CH, Elveback LR, et al. Epidemiology of systemic lupus erythematosus and other connective tissue diseases in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc. 1985 Feb;60(2):105-13. Resumo
10. Flower C, Hennis AJ, Hambleton IR, et al. Systemic lupus erythematosus in an African Caribbean population: incidence, clinical manifestations, and survival in the Barbados National Lupus Registry. Arthritis Care Res (Hoboken). 2012 Aug;64(8):1151-8.Texto completo Resumo
11. Izmirly PM, Parton H, Wang L, et al. Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis Rheumatol. 2021 Jun;73(6):991-6. Resumo
12. Masi AT, Kaslow RA. Sex effects in SLE: a clue to pathogenesis. Arthritis Rheum. 1978 May;21(4):480-4. Resumo
13. Costenbader KH, Feskanich D, Stampfer MJ, et al. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum. 2007 Apr;56(4):1251-62.Texto completo Resumo
14. Lawrence JS, Martins CL, Drake GL. A family survey of lupus erythematosus. 1. Heritability. J Rheumatol. 1987 Oct;14(5):913-21. Resumo
15. Deapen D, Escalante A, Weinrib L, et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum. 1992 Mar;35(3):311-8. Resumo
16. Kuo CF, Grainge MJ, Valdes AM, et al. Familial aggregation of systemic lupus erythematosus and coaggregation of autoimmune diseases in affected families. JAMA Intern Med. 2015 Sep;175(9):1518-26.Texto completo Resumo
17. Teruel M, Alarcón-Riquelme ME. The genetic basis of systemic lupus erythematosus: what are the risk factors and what have we learned. J Autoimmun. 2016 Nov;74:161-75. Resumo
18. Soni C, Reizis B. DNA as a self-antigen: nature and regulation. Curr Opin Immunol. 2018 Dec;55:31-7.Texto completo Resumo
19. Fan Y, Li LH, Pan HF, et al. Association of ITGAM polymorphism with systemic lupus erythematosus: a meta-analysis. J Eur Acad Dermatol Venereol. 2011 Mar;25(3):271-5. Resumo
20. Wang JM, Huang AF, Yuan ZC, et al. Association of IRF5 rs2004640 polymorphism and systemic lupus erythematosus: a meta-analysis. Int J Rheum Dis. 2019 Sep;22(9):1598-606. Resumo
21. Goropevšek A, Holcar M, Avčin T. The role of STAT signaling pathways in the pathogenesis of systemic lupus erythematosus. Clin Rev Allergy Immunol. 2017 Apr;52(2):164-81. Resumo
22. Kozyrev SV, Abelson AK, Wojcik J, et al. Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet. 2008 Feb;40(2):211-6. Resumo
23. Lee YH, Bae SC. Association between the functional ITGAM rs1143679 G/A polymorphism and systemic lupus erythematosus/lupus nephritis or rheumatoid arthritis: an update meta-analysis. Rheumatol Int. 2015 May;35(5):815-23. Resumo
24. Kyogoku C, Langefeld CD, Ortmann WA, et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet. 2004 Sep;75(3):504-7.Texto completo Resumo
25. Yung RL, Richardson BC. Drug-induced lupus. Rheum Dis Clin North Am. 1994 Feb;20(1):61-86. Resumo
26. Blomgren SE, Condemi JJ, Vaughan JH. Procainamide-induced lupus erythematosus: clinical and laboratory observations. Am J Med. 1972 Mar;52(3):338-48. Resumo
27. Sclienger RG, Bircher AJ, Meier CR. Minocycline-induced lupus: a systematic review. Dermatology. 2000;200(3):223-31. Resumo
28. Gordon MM, Porter D. Minocycline induced lupus: case series in the West of Scotland. J Rheumatol. 2001 May;28(5):1004-6. Resumo
29. McKellar G, Porter D, Burden D. Terbinafine as a cause of cutaneous lupus erythematosus. Rheumatology (Oxford). 2004 Feb;43(2):249. Resumo
30. Gunnarsson I, Nordmark B, Hassan Bakri A et al. Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment-the role of IL-10 and HLA. Rheumatology (Oxford). 2000 Aug;39(8):886-93.Texto completo Resumo
31. Siddiqui MA, Khan IA. Isoniazid-induced lupus erythematosus presenting with cardiac tamponade. Am J Ther. 2002 Mar-Apr;9(2):163-5. Resumo
32. Scheinfeld N. Impact of phenytoin therapy on the skin and skin disease. Expert Opin Drug Saf. 2004 Nov;3(6):655-65. Resumo
33. Pelizza L, De Luca P, La Pesa M, et al. Drug-induced systemic lupus erythematosus after 7 years of treatment with carbamazepine. Acta Biomed. 2006 Apr;77(1):17-9. Resumo
34. Illescas-Montes R, Corona-Castro CC, Melguizo-Rodríguez L, et al. Infectious processes and systemic lupus erythematosus. Immunology. 2019 Nov;158(3):153-60.Texto completo Resumo
35. Li ZX, Zeng S, Wu HX, et al. The risk of systemic lupus erythematosus associated with Epstein-Barr virus infection: a systematic review and meta-analysis. Clin Exp Med. 2019 Feb;19(1):23-36.Texto completo Resumo
36. Hanlon P, Avenell A, Aucott L, et al. Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus. Arthritis Res Ther. 2014 Jan 6;16(1):R3.Texto completo Resumo
37. Mohan C, Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol. 2015 Jun;11(6):329-41. Resumo
38. Lech M, Anders HJ. The pathogenesis of lupus nephritis. J Am Soc Nephrol. 2013 Sep;24(9):1357-66.Texto completo Resumo
39. Frangou E, Vassilopoulos D, Boletis J, et al. An emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus (SLE) and ANCA-associated vasculitides (AAV): Implications for the pathogenesis and treatment. Autoimmun Rev. 2019 Aug;18(8):751-60. Resumo
40. Boodhoo KD, Liu S, Zuo X. Impact of sex disparities on the clinical manifestations in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Medicine (Baltimore). 2016 Jul;95(29):e4272.Texto completo Resumo
41. Haugaard JH, Kofoed K, Gislason G, et al. Association between drug use and subsequent diagnosis of lupus erythematosus. JAMA Dermatol. 2020 Nov 1;156(11):1199-207.Texto completo Resumo
42. D'Cruz DP, Khamashta MA, Hughes GRV. Systemic lupus erythematosus. Lancet. 2007 Feb 17;369(9561):587-96. Resumo
43. Jiang F, Li S, Jia C. Smoking and the risk of systemic lupus erythematosus: an updated systematic review and cumulative meta-analysis. Clin Rheumatol. 2015 Nov;34(11):1885-92. Resumo
44. Parisis D, Bernier C, Chasset F, et al. Impact of tobacco smoking upon disease risk, activity and therapeutic response in systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 2019 Nov;18(11):102393. Resumo
45. Harel-Meir M. Sherer Y, Shoenfeld Y. Tobacco smoking and autoimmune disease. Nat Clin Pract Rheumatol. 2007 Dec;3(12):707-15. Resumo
46. Montes RA, Mocarzel LO, Lanzieri PG, et al. Smoking and its association with morbidity in systemic lupus erythematosus evaluated by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index: preliminary data and systematic review. Arthritis Rheumatol. 2016 Feb;68(2):441-8.Texto completo Resumo
47. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019 Jun;78(6):736-45.Texto completo Resumo
48. McKinley PS, Ouellette SC, Winkel GH. The contributions of disease activity, sleep patterns and depression to fatigue in SLE: a proposed model. Arthritis Rheum. 1995 Jun;38(6):826-34. Resumo
49. Leuchten N, Milke B, Winkler-Rohlfing B, et al. Early symptoms of systemic lupus erythematosus (SLE) recalled by 339 SLE patients. Lupus. 2018 Aug;27(9):1431-6. Resumo
50. Zandman-Goddard G, Schoenfeld Y. SLE and infections. Clin Rev Allergy Immunol. 2003 Aug;25(1):29-40. Resumo
51. Estes D, Christian CL. The natural history of systemic lupus erythematosus by prospective analysis. Medicine (Baltimore). 1971 Mar;50(2):85-95. Resumo
52. Vitali C, Doria A, Tincani A. International survey on the management of patients with SLE. I. General data on the participating centers and the results of a questionnaire regarding mucocutaneous involvement. Clin Exp Rheumatol. 1996 Nov-Dec;14(suppl 16):S17-22. Resumo
53. Dubois EL, Tuffanelli DL. Clinical manifestations of SLE: computer analysis of 520 cases. JAMA. 1964 Oct 12;190:104-11. Resumo
54. Kampylafka EI, Alexopoulos H, Kosmidis ML, et al. Incidence and prevalence of major central nervous system involvement in systemic lupus erythematosus: a 3-year prospective study of 370 patients. PLoS One. 2013;8(2):e55843.Texto completo Resumo
55. Boeke A, Pullen B, Coppes L, et al. Catatonia associated with systemic lupus erythematosus (SLE): a report of two cases and a review of the literature. Psychosomatics. 2018 Nov;59(6):523-30.Texto completo Resumo
56. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 1999 Feb;42(2):338-46.Texto completo Resumo
57. Gu MM, Wang XP, Cheng QY, et al. A meta-analysis of cardiovascular events in systemic lupus erythematosus. Immunol Invest. 2019 Jul;48(5):505-20. Resumo
58. Li H, Tong Q, Guo L, et al. Risk of coronary artery disease in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Am J Med Sci. 2018 Nov;356(5):451-63. Resumo
59. Yazdany J, Pooley N, Langham J, et al. Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis. RMD Open. 2020 Sep;6(2):e001247.Texto completo Resumo
60. Lu X, Wang Y, Zhang J, et al. Patients with systemic lupus erythematosus face a high risk of cardiovascular disease: a systematic review and meta-analysis. Int Immunopharmacol. 2021 May;94:107466. Resumo
61. Memet B, Ginzler EM. Pulmonary manifestations of systemic lupus erythematosus. Semin Respir Crit Care Med. 2007 Aug;28(4):441-50. Resumo
62. Duron L, Cohen-Aubart F, Diot E, et al. Shrinking lung syndrome associated with systemic lupus erythematosus: a multicenter collaborative study of 15 new cases and a review of the 155 cases in the literature focusing on treatment response and long-term outcomes. Autoimmun Rev. 2016 Oct;15(10):994-1000. Resumo
63. Beyan E, Beyan C, Turan M. Hematological presentation in systemic lupus erythematosus and its relationship with disease activity. Hematology. 2007 Jun;12(3):257-61. Resumo
64. Hallegua DS, Wallace DJ. Gastrointestinal manifestations of systemic lupus erythematosus. Curr Opin Rheumatol. 2000 Sep;12(5):379-85. Resumo
65. Kudsi M, Nahas LD, Alsawah R, et al. The prevalence of oral mucosal lesions and related factors in systemic lupus erythematosus patients. Arthritis Res Ther. 2021 Sep 3;23(1):229.Texto completo Resumo
66. Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum. 1997 Sep;40(9):1601-11. Resumo
67. Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis. 2010 Aug;69(8):1420-2. Resumo
68. American College of Rheumatology. Methodology of testing for antinuclear antibodies. 2019 [internet publication].Texto completo
69. Smeenk R, Brinkman K, van den Brink H, et al. Antibodies to DNA in patients with systemic lupus erythematosus: their role in the diagnosis, the follow-up and the pathogenesis of the disease. Clin Rheumatol. 1990 Mar;9(1 suppl 1):100-10. Resumo
70. Eaton RB, Schnneider G, Schur PH. Enzyme immunoassay for antibodies to native DNA. Specificity and quality of antibodies. Arthritis Rheum. 1983 Jan;26(1):52-62. Resumo
71. Choi MY, FitzPatrick RD, Buhler K, et al. A review and meta-analysis of anti-ribosomal P autoantibodies in systemic lupus erythematosus. Autoimmun Rev. 2020 Mar;19(3):102463.Texto completo Resumo
72. Ho RC, Thiaghu C, Ong H, et al. A meta-analysis of serum and cerebrospinal fluid autoantibodies in neuropsychiatric systemic lupus erythematosus. Autoimmun Rev. 2016 Feb;15(2):124-38. Resumo
73. Buleu F, Sirbu E, Caraba A, et al. Heart involvement in inflammatory rheumatic diseases: a systematic literature review. Medicina (Kaunas). 2019 Jun 6;55(6):249.Texto completo Resumo
74. Simundic AM, Bölenius K, Cadamuro J, et al. Joint EFLM-COLABIOCLI recommendation for venous blood sampling. Clin Chem Lab Med 2018;56(12):2015-38. Resumo
75. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with SLE: comparison with the Framingham study. Am J Epidemiol. 1997 Mar 1;145(5):408-15.Texto completo Resumo
76. Hochberg MC, Boyd RE, Ahearn JM, et al. Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine (Baltimore). 1985 Sep;64(5):285-95. Resumo
77. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003 Sep;82(5):299-308.Texto completo Resumo
78. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002 Apr;46(4):1019-27. Resumo
79. von Mühlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum. 1995 Apr;24(5):323-58. Resumo
80. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the anti-phospholipid syndrome. Blood. 2007 Jan 15;109(2):422-30.Texto completo Resumo
81. van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis. 2017 Mar;76(3):554-61. Resumo
82. van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014 Jun;73(6):958-67. Resumo
83. Lehmann P, Homey B. Clinic and pathophysiology of photosensitivity in lupus erythematosus. Autoimmun Rev. 2009 May;8(6):456-61. Resumo
84. Kuhn A, Gensch K, Haust M, et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. J Am Acad Dermatol. 2011 Jan;64(1):37-48.Texto completo Resumo
85. Rodríguez Huerta MD, Trujillo-Martín MM, Rúa-Figueroa Í, et al. Healthy lifestyle habits for patients with systemic lupus erythematosus: a systemic review. Semin Arthritis Rheum. 2016 Feb;45(4):463-70. Resumo
86. Wang XR, Xiao JP, Zhang JJ, el. Decreased serum/plasma vitamin D levels in SLE patients: a meta-analysis. Curr Pharm Des. 2018;24(37):4466-73. Resumo
87. Islam MA, Khandker SS, Alam SS, et al. Vitamin D status in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Autoimmun Rev. 2019 Nov;18(11):102392. Resumo
88. Sousa JR, Cunha Rosa EP, Costa Nunes IF, et al. Effect of vitamin D supplementation on patients with systemic lupus erythematosus: a systematic review. Rev Bras Reumatol Engl Ed. Sep-Oct 2017;57(5):466-71.Texto completo Resumo
89. de Medeiros MCS, Medeiros JCA, de Medeiros HJ, et al. Dietary intervention and health in patients with systemic lupus erythematosus: a systematic review of the evidence. Crit Rev Food Sci Nutr. 2019;59(16):2666-73. Resumo
90. Zheng R, Gonzalez A, Yue J, et al. Efficacy and safety of vitamin D supplementation in patients with systemic lupus erythematosus: a meta-analysis of randomized controlled trials. Am J Med Sci. 2019 Aug;358(2):104-14. Resumo
91. Duarte-García A, Myasoedova E, Karmacharya P, et al. Effect of omega-3 fatty acids on systemic lupus erythematosus disease activity: a systematic review and meta-analysis. Autoimmun Rev. 2020 Dec;19(12):102688. Resumo
92. Gu M, Cheng Q, Wang X, et al. The impact of SLE on health-related quality of life assessed with SF-36: a systemic review and meta-analysis. Lupus. 2019 Mar;28(3):371-82. Resumo
93. Li Z, Yang Y, Dong C, et al. The prevalence of suicidal ideation and suicide attempt in patients with rheumatic diseases: a systematic review and meta-analysis. Psychol Health Med. 2018 Oct;23(9):1025-36. Resumo
94. Fangtham M, Kasturi S, Bannuru RR, et al. Non-pharmacologic therapies for systemic lupus erythematosus. Lupus. 2019 May;28(6):703-12.Texto completo Resumo
95. Poole JL, Bradford JD, Siegel P. Effectiveness of occupational therapy interventions for adults with systemic lupus erythematosus: a systematic review. Am J Occup Ther. 2019 Jul/Aug;73(4). Resumo
96. Chasset F, Francès C, Barete S, et al. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. J Am Acad Dermatol. 2015 Apr;72(4):634-9. Resumo
97. Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol. 2000 Jun;42(6):983-7. Resumo
98. Rodríguez SC, Olguín AM, Miralles CP, et al. Characteristics of meningitis caused by ibuprofen: report of 2 cases with recurrent episodes and review of the literature. Medicine (Baltimore). 2006 Jul;85(4):214-20. Resumo
99. Hoffman M, Gray RG. Ibuprofen-induced meningitis in mixed connective tissue disease. Clin Rheumatol. 1982 Jun;1(2):128-30. Resumo
100. Wasner CK. Ibuprofen, meningitis, and systemic lupus erythematosus. J Rheumatol. Summer 1978;5(2):162-4. Resumo
101. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010 Jan;69(1):20-8. Resumo
102. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014 Dec;132(12):1453-60.Texto completo Resumo
103. Kim JW, Kim YY, Lee H, et al. Risk of retinal toxicity in longterm users of hydroxychloroquine. J Rheumatol. 2017 Nov;44(11):1674-9.Texto completo Resumo
104. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011 Feb 26;377(9767):721-31. Resumo
105. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15;61(9):1168-78.Texto completo Resumo
106. Wallace DJ, Ginzler EM, Merrill JT, et al. Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2019 Jul;71(7):1125-34.Texto completo Resumo
107. Iwata S, Saito K, Hirata S, et al. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus. Lupus. 2018 Apr;27(5):802-11. Resumo
108. National Institute for Health and Care Excellence. Belimumab for treating active autoantibody-positive systemic lupus erythematosus. Technology appraisal guidance [TA752]. Dec 2021 [internet publication].Texto completo
109. Singh JA, Shah NP, Mudano AS. Belimumab for systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 Feb 25;2(2):CD010668.Texto completo Resumo
110. Urowitz MB, Ohsfeldt RL, Wielage RC, et al. Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis. Ann Rheum Dis. 2019 Mar;78(3):372-9.Texto completo Resumo
111. Bruce IN, Mak VC, Hallett DC, et al. Factors associated with fatigue in patients with systemic lupus erythematosus. Ann Rheum Dis. 1999 Jun;58(6):379-81.Texto completo Resumo
112. Zonana-Nacach A, Roseman JM, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups, VI: factors associated with fatigue within five year of criteria diagnosis. Lupus. 2000;9(2):101-9. Resumo
113. Zhao Q, Deng N, Chen S, et al. Systemic lupus erythematosus is associated with negatively variable impacts on domains of sleep disturbances: a systematic review and meta-analysis. Psychol Health Med. 2018 Jul;23(6):685-97. Resumo
114. Cojocaru M, Cojocaru IM, Silosi I, et al. Manifestations of systemic lupus erythematosus. Maedica (Bucur). 2011 Oct;6(4):330-6.Texto completo Resumo
115. William HJ, Egger MJ, Singer JZ, et al. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J Rheumatol. 1994 Aug;21(8):1457-62. Resumo
116. Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991 Jan 17;324(3):150-4.Texto completo Resumo
117. Carneiro JR, Sato EI. Double-blind, randomised, placebo controlled trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1999 Jun;26(6):1275-9. Resumo
118. Lupus UK. The mouth and lupus [internet publication].Texto completo
119. Altenburg A, El-Haj N, Micheli C, et al. The treatment of chronic recurrent oral aphthous ulcers. Dtsch Arztebl Int. 2014 Oct 3;111(40):665-73.Texto completo Resumo
120. Hannon CW, McCourt C, Lima HC, et al. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 Mar 9;(3):CD007478.Texto completo Resumo
121. Henderson LK, Masson P, Craig JC, et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2013 Jan;61(1):74-87. Resumo
122. Tunnicliffe DJ, Palmer SC, Henderson L, et al. Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database Syst Rev. 2018 Jun 29;(6):CD002922.Texto completo Resumo
123. Jiang YP, Zhao XX, Chen RR, et al. Comparative efficacy and safety of mycophenolate mofetil and cyclophosphamide in the induction treatment of lupus nephritis: a systematic review and meta-analysis. Medicine (Baltimore). 2020 Sep 18;99(38):e22328.Texto completo Resumo
124. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64:797-808.Texto completo Resumo
125. Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020 Jun;79(6):713-23.Texto completo Resumo
126. Kasitanon N, Fine DM, Haas M, et al. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus. 2006;15(6):366-70. Resumo
127. Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020 Sep 17;383(12):1117-28.Texto completo Resumo
128. Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015 Jan 6;162(1):18-26. Resumo
129. Tian SY, Feldman BM, Beyene J, et al. Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: a systematic review and network metaanalysis. J Rheumatol. 2014 Oct;41(10):1998-2007. Resumo
130. Zhang X, Ji L, Yang L, et al. The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis. Int Urol Nephrol. 2016 May;48(5):731-43. Resumo
131. Lee YH, Song GG. Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: a Bayesian network meta-analysis of randomized controlled trials. Lupus. 2015 Dec;24(14):1520-8. Resumo
132. Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis. 2011 Feb;57(2):235-44. Resumo
133. Zhou T, Lin S, Yang S, et al. Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis. Drug Des Devel Ther. 2019 Mar 12;13:857-69.Texto completo Resumo
134. Song GG, Lee YH. Comparison of treatment response and serious infection using tacrolimus, tacrolimus with mycophenolate mofetil, in comparison to cyclophosphamide as induction treatment for lupus nephritis. Int J Clin Pharmacol Ther. 2020 Oct;58(10):550-6. Resumo
135. Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppresion in lupus nephritis: results from the MAINTAIN Nephritis trial. Ann Rheum Dis. 2010 Dec;69(12):2083-9.Texto completo Resumo
136. Magro-Checa C, Zirkzee EJ, Huizinga TW, et al. Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives. Drugs. 2016 Mar;76(4):459-83.Texto completo Resumo
137. Chen Z, Zhong H, Dong G. Thrombocytopenia as a prognostic marker for systemic lupus erythematosus: a systematic review and meta-analysis. Am J Med Sci. 2019 Jun;357(6):461-7. Resumo
138. ClinicalTrials.gov. Efficacy and safety of two doses of anifrolumab compared to placebo in adult subjects with active systemic lupus erythematosus. December 2019 [internet publication].Texto completo
139. Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020 Jan 16;382(3):211-21.Texto completo Resumo
140. Chatham WW, Furie R, Saxena A, et al. Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: results of a phase II open-label extension study. Arthritis Rheumatol. 2021 May;73(5):816-25.Texto completo Resumo
141. Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021 May 29;397(10289):2070-80. Resumo
142. Lee YH, Bae SC. Comparative efficacy and safety of baricitinib 2 mg and 4 mg in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Z Rheumatol. 2018 May;77(4):335-42. Resumo
143. Emery P, Blanco R, Maldonado Cocco J, et al. Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis. RMD Open. 2017 Mar 21;3(1):e000410.Texto completo Resumo
144. Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016 Mar 31;374(13):1243-52.Texto completo Resumo
145. Dougados M, van der Heijde D, Chen YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017 Jan;76(1):88-95.Texto completo Resumo
146. Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018 Jul 21;392(10143):222-31. Resumo
147. ClinicalTrials.gov. A study of baricitinib in participants with systemic lupus erythematosus (BRAVE II). November 2021 [internet publication].Texto completo
148. ClinicalTrials.gov. A study of baricitinib in participants with systemic lupus erythematosus (SLE) (SLE-BRAVE-X). November 2021 [internet publication].Texto completo
149. ClinicalTrials.gov. A study to evaluate the safety and efficacy of obinutuzumab compared with placebo in participants with lupus nephritis (LN). November 2021 [internet publication].Texto completo
150. Furie R, Aroca G, Alvarez A, et al. Two-year results from a randomized, controlled study of obinutuzumab for proliferative lupus nephritis. Abstract number 0988: ACR Convergence 2020. Arthritis Rheumatol. 2020; 72 (suppl 10).Texto completo
151. ClinicalTrials.gov. Study of EQ001 (itolizumab) in systemic lupus erythematosus with or without active proliferative nephritis (EQUALISE). November 2021 [internet publication].Texto completo
152. Merrill JT, Shanahan WR, Scheinberg M, et al. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018 Jun;77(6):883-9.Texto completo Resumo
153. Department of Health. Clinical guidelines for immunoglobulin use (2nd edition). May 2008 [internet publication].Texto completo
154. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 5 year period. A multicentre prospective study of 1000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1999 May;78(3):167-75. Resumo
155. Cervera R, Abarca-Costalago M, Abramovicz D, et al. Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project". AAutoimmun Rev. 2006 Mar;5(3):180-6. Resumo
156. Lee YH, Choi SJ, Ji JD, et al. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus. 2016 Jun;25(7):727-34. Resumo
157. Fors Nieves CE, Izmirly PM. Mortality in systemic lupus erythematosus: an updated review. Curr Rheumatol Rep. 2016 Apr;18(4):21. Resumo
158. Qian J, Wang Y, Huang C, et al. Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: a PRISMA-compliant systematic review and meta-analysis. Autoimmun Rev. 2016 Mar;15(3):250-7. Resumo
159. Ballocca F, D'Ascenzo F, Moretti C, et al. Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Eur J Prev Cardiol. 2015 Nov;22(11):1435-41.Texto completo Resumo
160. Bernatsky S, Joseph L, Boivin JF, et al. The relationship between cancer and medication exposures in systemic lupus erythematosus: a case-cohort study. Ann Rheum Dis. 2008 Jan;67(1):74-9. Resumo
161. Schneider V, Levesque LE, Zhang B, et al. Association of selective and conventional non-steroidal anti inflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol. 2006 Nov 1;164(9):881-9.Texto completo Resumo
162. Breuer GS, Baer A, Dahan D, Nesher G. Lupus-associated pancreatitis. Autoimmun Rev. 2006 May;5(5):314-8. Resumo
163. Nesher G, Breuer GS, Temprano K, et al. Lupus-associated pancreatitis. Semin Arthritis Rheum. 2006 Feb;35(4):260-7. Resumo
164. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995 Apr 13;332(15):993-7.Texto completo Resumo
165. Katsifis GE, Tzioufas AG. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus. 2004;13(9):673-8. Resumo
166. Manger K, Wildt L, Kalden JR, et al. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Autoimmun Rev. 2006 Apr;5(4):269-72. Resumo
167. Soares PM, Borba EF, Bonfa E, et al. Gonad evaluation in male systemic lupus erythematosus. Arthritis Rheum. 2007 Jul;56(7):2352-61.Texto completo Resumo
168. Oshiro BT, Silver RM, Scott JR, et al. Antiphospholipid antibodies and fetal death. Obstet Gynecol. 1996 Apr;87(4):489-93. Resumo
169. Out HJ, Bruinse HW, Christiaens GC, et al. A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol. 1992 Jul;167(1):26-32. Resumo
170. Kozora E, Ellison MC, West S. Depression, fatigue, and pain in systemic lupus erythematosus (SLE): relationship to the American College of Rheumatology SLE neuropsychological battery. Arthritis Rheum. 2006 Aug 15;55(4):628-35.Texto completo Resumo
171. Wang X, Yan S, Liu C, et al. Fracture risk and bone mineral density levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Osteoporos Int. 2016 Apr;27(4):1413-23. Resumo
172. Henegar CE, Eudy AM, Kharat V, et al. Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review. Lupus. 2016 May;25(6):617-26. Resumo
173. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptive in women with systemic lupus erythematosus. N Engl J Med. 2005 Dec 15;353(24):2550-8.Texto completo Resumo
174. Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med. 2005 Dec 15;353(24):2539-49.Texto completo Resumo
175. Clowse ME, Magder L, Whitter F, et al. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006 Nov;54(11):3640-7.Texto completo Resumo
176. Battafarano DF, Battafarano NJ, Larsen L et al. Antigen specific antibody responses in lupus patients following immunization. Arthritis Rheum. 1998 Oct;41(10):1828-34. Resumo
177. Holvast A, Huckriede A, Wilschut J, et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis. 2006 Jul;65(7):913-8.Texto completo Resumo
178. Mathian A, Pha M, Amoura Z. Lupus and vaccinations. Curr Opin Rheumatol. 2018 Sep;30(5):465-70. Resumo
179. Huang Y, Wang H, Wan L, et al. Is systemic lupus erythematosus associated with a declined immunogenicity and poor safety of influenza vaccination? A systematic review and meta-analysis. Medicine (Baltimore). 2016 May;95(19):e3637.Texto completo Resumo
180. Pugès M, Biscay P, Barnetche T, et al. Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis. Rheumatology (Oxford). 2016 Sep;55(9):1664-72.Texto completo Resumo
181. Senecal JL, Bertrand C, Coutlee F. Severe exacerbation of systemic lupus erythematosus after hepatitis B vaccination and importance of pneumococcal vaccination in patients with autosplenectomy. Arthritis Rheum. 1999 Jun;42(6):1307-8.Texto completo Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal